- Home
- CNTX vs NTRB Comparison
CNTX vs NTRB Comparison
Compare CNTX & NTRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNTX
- NTRB
- Stock Information
- Founded
- CNTX 2015
- NTRB 2016
- Country
- CNTX United States
- NTRB United States
- Employees
- CNTX N/A
- NTRB N/A
- Industry
- CNTX Biotechnology: Pharmaceutical Preparations
- NTRB Industrial Specialties
- Sector
- CNTX Health Care
- NTRB Health Care
- Exchange
- CNTX Nasdaq
- NTRB Nasdaq
- Market Cap
- CNTX 75.6M
- NTRB 71.8M
- IPO Year
- CNTX 2021
- NTRB N/A
- Fundamental
- Price
- CNTX $0.82
- NTRB $6.39
- Analyst Decision
- CNTX Strong Buy
- NTRB Buy
- Analyst Count
- CNTX 5
- NTRB 1
- Target Price
- CNTX $5.25
- NTRB $13.00
- AVG Volume (30 Days)
- CNTX 162.2K
- NTRB 36.9K
- Earning Date
- CNTX 11-05-2025
- NTRB 09-05-2025
- Dividend Yield
- CNTX N/A
- NTRB N/A
- EPS Growth
- CNTX N/A
- NTRB N/A
- EPS
- CNTX N/A
- NTRB N/A
- Revenue
- CNTX N/A
- NTRB $2,398,437.00
- Revenue This Year
- CNTX N/A
- NTRB $560.75
- Revenue Next Year
- CNTX N/A
- NTRB $588.39
- P/E Ratio
- CNTX N/A
- NTRB N/A
- Revenue Growth
- CNTX N/A
- NTRB 18.92
- 52 Week Low
- CNTX $0.49
- NTRB $2.98
- 52 Week High
- CNTX $2.59
- NTRB $9.42
- Technical
- Relative Strength Index (RSI)
- CNTX 52.03
- NTRB 42.80
- Support Level
- CNTX $0.81
- NTRB $5.81
- Resistance Level
- CNTX $0.94
- NTRB $6.59
- Average True Range (ATR)
- CNTX 0.05
- NTRB 0.31
- MACD
- CNTX -0.01
- NTRB 0.05
- Stochastic Oscillator
- CNTX 10.36
- NTRB 66.74
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
About NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.